Urethral Drug-Coated Balloons for the Treatment of Urethral Stricture(s)
Customize your policy alerts
Sign up for all blue cross blue shield - south dakota policy alerts
Know when blue cross blue shield - south dakota releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs coverage determinations for urethral drug-coated balloons (e.g., Optilume®) to treat obstructive urinary symptoms from anterior urethral strictures for Wellmark/Blue Cross Blue Shield - South Dakota members.
No material clinical or coverage changes in this revision.
Coverage Determinations
inv-01: Investigational / Not covered as medically necessary
Covered when ALL of the following are met:
Includes Optilume®
inv-02: Coverage considerations aligned to trial populations and guideline recommendations
Consider DCB therapy for patients meeting STUDY/GUIDELINE‑aligned characteristics:
Patient selection
- Stricture characteristics: Short strictures, generally <3 cm in length; trial eligibility included anterior strictures <12 Fr in diameter and <3 cm in length.<3 cm
ROBUST III eligibility and guideline emphasis on short/bulbar strictures.
- Prior treatments: Recurrent strictures after at least two prior endoscopic treatments (dilation or DVIU) as specified in guideline recommendations and the randomized trial enrollment criteria.>=2 prior endoscopic treatments
EAU/AUA guidance and ROBUST III trial population.
Reflects comparator context from trials and guideline positioning.
Optilume® is contraindicated in individuals with known hypersensitivity to paclitaxel or structurally related compounds. The device is also contraindicated in patients with certain urologic implants (for example, penile implants or artificial urinary sphincters) where placement or interaction with the device could pose risk.
The clinical evidence primarily enrolled patients with anterior (typically bulbar) short strictures, and most trial subjects had bulbar strictures; therefore applicability to non-bulbar locations or longer strictures (>3 cm) is uncertain. The randomized controlled trial(s) compared the drug-coated balloon to endoscopic management (dilation or DVIU) and did not directly compare DCBs to urethroplasty, limiting conclusions about comparative effectiveness for longer or more complex strictures.
The policy documentation does not list additional explicit clinical exclusions beyond device-specific contraindications (e.g., paclitaxel hypersensitivity and presence of certain urologic implants).
Although systematic reviews and an RCT (ROBUST III) report reduced recurrence and improved urinary flow and symptom scores with Optilume® versus endoscopic management, the overall body of evidence has limitations—short follow-up in many studies, limited numbers of randomized comparisons, and lack of direct comparison with urethroplasty. Because of these evidence gaps, the use of urethral drug-coated balloons cannot be concluded to improve net health outcomes.
Given the available data, drug-coated balloons are not supported for unrestricted use across all anterior urethral strictures. Evidence is strongest for short bulbar strictures as studied in trials; therefore DCBs are not considered a universal standard treatment for all anterior strictures and should be considered investigational outside the studied populations and contexts.
The policy cites key studies and guideline assessments (including the ROBUST trials and recent guideline amendments) that report favorable short-term outcomes with DCBs but note limitations such as limited generalizability, higher hematuria in the treatment arm, and lack of long-term comparative data. These references inform the investigational determination without restating a specific ‘‘Not Medically Necessary’’ phrasing in each citation.
Coding and Billing
| 52284 | Cystourethroscopy, with mechanical urethral dilation and urethral therapeutic drug delivery by drug-coated balloon catheter for urethral stricture or stenosis, male, including fluoroscopy, when performed. |
| No code(s) | HCPCS: No specific HCPCS code listed |
| Surgery | Type of Service |
| Outpatient | Place of Service |
Provider Requirements and Operational Notes
Prior Authorization
Prior approval is not applicable for this policy; however, the urethral drug-coated balloon (e.g., Optilume®) is designated investigational and may be denied as the evidence is insufficient to determine improvement in net health outcomes.
- Investigational designation — potential for denial.
Prior Authorization Recommended for Recurrent Bulbar Strictures
For recurrent bulbar urethral strictures (<3 cm) the 2023 AUA guideline amendment states surgeons may offer dilation or DVIU combined with drug-coated balloons (Conditional Recommendation; Grade B). When used in this guideline-aligned scenario, prior authorization is recommended to ensure appropriate patient selection and documentation of prior endoscopic treatments.
- AUA 2023 guideline: recurrent bulbar strictures <3 cm — DCB may be offered.
- Recommend prior authorization when DCB is used after prior endoscopic treatments (e.g., ≥1 prior dilation/DVIU).
Prior Authorization and Billing
When billing, report the appropriate CPT code (52284) and outpatient place/type of service. Prior authorization is not required per policy header, but accurate coding and place of service are necessary to avoid coding-related denials.
- Report CPT 52284: Cystourethroscopy with mechanical urethral dilation and therapeutic drug delivery by drug-coated balloon.
- Place of Service: Outpatient (surgery).
- Ensure accurate procedure details on the claim to reduce denial risk.
Evidence Insufficiency and Coverage Stance
The body of evidence includes one RCT showing reduced stricture recurrence and improved flow and symptom scores versus endoscopic management, but limitations (primarily short follow-up beyond 2 years, predominance of bulbar strictures, and absence of comparison with urethroplasty) leave uncertainty about long-term net health outcome benefit. Evidence is therefore insufficient to support routine coverage.
- RCT (ROBUST III) showed anatomical success at 6 months (74.6% DCB vs 26.8% control) and higher freedom from repeat intervention at 1 year.
- Limitations: limited long-term data, generalizability mostly to bulbar strictures, no direct comparison to urethroplasty.
Existing Therapy Context
Standard initial treatments for short (<2 cm) bulbar strictures include urethral dilation, DVIU, or urethroplasty. Drug-coated balloons are positioned as an adjunctive treatment following prior endoscopic therapies to attempt to reduce high recurrence rates.
- Initial non‑urgent treatment for short bulbar strictures: dilation, DVIU, or urethroplasty.
- DCB (Optilume®) considered an adjunctive option to address recurrence after endoscopic treatments.
Comparators and Guideline Positioning
Comparators include uncoated balloon dilation, DVIU (endoscopic management), and urethroplasty. Clinical trials generally used uncoated balloon dilation or other endoscopic management as the control; DCB has not been compared directly to urethroplasty in randomized trials.
- Comparator treatments: uncoated balloon dilation, endoscopic management (DVIU), urethroplasty.
- RCT controls were standard endoscopic treatments (serial dilation, uncoated balloon, DVIU).
Clinical Background
Urethral strictures are focal narrowing of the urethral lumen that often produce lower urinary tract symptoms such as a decreased urinary stream, hesitancy, incomplete bladder emptying, and recurrent urinary tract infections. Etiologies include idiopathic and iatrogenic causes. Management depends on stricture location and length; short bulbar strictures are commonly treated with dilation, DVIU, or urethroplasty, but recurrence rates are high and newer adjunctive options such as paclitaxel-coated urethral balloons have been evaluated to reduce recurrence.
Definitions and Device Status
Policy Revision History
Policy renewed following annual review.
New medical policy created for urethral drug-coated balloons (Optilume®).
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.